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Abstract
Background: Smokers with airway obstruction are at a higher risk of lung cancer than smokers without airway
obstruction. Inflammation plays a key role in lung carcinogenesis. This single-center study prospectively assessed (i)
the relationship between smoking exposure and the loss of forced expiratory volume in 1 s (FEV1) in determining
lung cancer risk and (ii) the effect of lung cancer on systemic inflammation.
Methods: The study group comprised 475 consecutively enrolled patients with cancer who presented with
pulmonary or cardiac symptoms. The effects of smoking exposure and FEV1 loss on the predicted lung
cancer risk were assessed using multiple logistic regression analysis. C-reactive protein (CRP) was used as a
marker of inflammation.
Results: The prevalence of lung cancer was 0.23. The lung cancer risk increased with the number of pack
years and FEV1 loss (p < 0.01). Moving from the 5th (−22% of the predicted value) to the 95th percentile of
FEV1 loss (56% of the predicted value) increased lung cancer risk from 0.07 to 0.23 (Δ = 0.16) at 0 pack years
and from 0.39 to 0.73 (Δ = 0.34) at 70 pack years (95th percentile). The values for Δ peaked at 61 pack years
(0.34) and then decreased with a further increase in smoking exposure, without reaching the zero mark.
Patients with lung cancer were more likely to have a CRP level above the median (4.05 mg/L) than patients
with other cancers (adjusted odds ratio = 2.67).
Conclusions: Systemic inflammation is more pronounced in patients with lung cancer than in patients with
other cancers. The effect of FEV1 loss on the patients’ predicted risks of lung cancer increases with increasing
smoking exposure. Measurements of FEV1 loss are useful to identify patients facing an increased risk of
developing lung cancer.
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Background
Chronic obstructive pulmonary disease (COPD) and lung
cancer co-occur in smokers more frequently than if they
were independently caused by smoking. According to epi-
demiological studies, the lung cancer risk increases with
decreasing forced expiratory volume in 1 s (FEV1) after
adjusting for the smoking dosage [1, 2]. As reported in a
meta-analysis, even a slight decrease in the FEV1 from >
100 to 90% of the predicted value increased the adjusted
risk for lung cancer 1.30-fold in men and 2.64-fold in
women [3]. These risks were increased by 2.23-fold in
men and 3.97-fold in women exhibiting an FEV1 of 70%
of the predicted value. In addition to smoking exposure,
several mechanisms may account for the link between
lung cancer and FEV1 loss, including a genetic overlap be-
tween both entities. Shared genetic pathways to disease
development may predispose the small airways of suscep-
tible smokers to oxidative stress and the accumulation of
inflammatory cells. Fibrosis, inflammation of the small air-
ways and the presence of luminal exudates are both fea-
tures of COPD and carcinogenic risk factors. The extents
to which these processes occur correlate with the rate of
FEV1 loss [4]. Therefore, FEV1 loss may be considered a
quantitative surrogate marker of the smoking-induced
carcinogenic damage to the airways. The purpose of this
study was to further delineate the relationship between
smoking exposure and FEV1 loss in determining patients’
risks of lung cancer. Secondary objectives were to de-
termine (i) whether patients with lung cancer differ
from patients with other cancers with respect to the
degree of systemic inflammation, and (ii) whether the
effect of smoking exposure on FEV1 loss differs in




This prospective single-center study included 586
consecutively enrolled patients with a history of either
previous or active malignant disease who were referred
from primary care, oncology, or radio-oncology to the
pulmonology or cardiology service of an academic
teaching hospital between May 2007 and October 2014
because of dyspnea, cough, chest pain, pulse irregular-
ities, or exercise intolerance. All but 8 patients were
outpatients, and none were confined to bed. We ex-
cluded 111 patients for the reasons presented in Fig. 1,
resulting in the inclusion of 475 patients in the
analysis.
Diagnostic procedures
The patients underwent an examination to identify lung
and heart disease that included a medical history, smoking
history, chest X-ray and spirometry, as well as an
Fig. 1 Patient selection algorithm. 1The patient did not turn up for lung function testing (n = 2), was deemed too sick for spirometry (n = 4), or
was deemed too sick to sit in the plethysmograph, but the TLC % predicted value was required for adjusting the FEV1 % predicted value in
patients with restrictive lung disease (n = 11)
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electrocardiogram and an echocardiogram, as previously
described [5]. Further tests were performed when indicated.
The European Respiratory Society predicted values for nor-
mal lung volumes were utilized [6]. Patients exhibiting an
FEV1 < 80% of the predicted value or an FEV1/forced ex-
piratory vital capacity (FVC) ratio < 0.70 and patients with a
history or suspicion of bronchial asthma underwent bron-
chodilator testing with 400 μg of salbutamol from a
metered dose inhaler via aVolumatic spacer (GlaxoSmithK-
line, Munich, Germany). The maximum values for FEV1
and vital capacity (VC) obtained either before or after bron-
chodilator testing were used for further analysis. Patients
with a VC < 80% of the predicted value underwent body
plethysmography to determine total lung capacity (TLC).
In patients exhibiting both an FEV1 < 80% of the predicted
value and a TLC < 80% of the predicted value, the FEV1 %
predicted value was adjusted for the degree of restriction (i)
by dividing the FEV1 % predicted value by [0.01 x TLC %
predicted] if the TLC % predicted value was greater than
the VC % predicted value and (ii) by dividing the FEV1 %
predicted value by [0.01 x VC % predicted] if the VC % pre-
dicted value was greater than or equal to the TLC % pre-
dicted value. The lifetime active smoking exposure was
measured in pack years. Assuming 20 cigarettes per pack,
this value is equal to the number of packs of cigarettes
smoked per day multiplied by years of consumption. A
web-based pack year calculator (www.smokingpackyears.-
com/) that accounted for varying smoking habits over the
years was used. The FEV1 loss % predicted was calculated
as [100% - FEV1 % predicted].
The serum C-reactive protein (CRP) levels were mea-
sured using a highly sensitive assay (COBAS Integra,
CRPLX, Roche Diagnostics, Mannheim, Germany). The
lower limit of detection for the CRP levels was 0.71 mg/
L. A value of 0.35 mg/L was prospectively assigned to 45
patients with undetectable CRP levels, as previously
done in this cohort [5]. The estimated glomerular filtra-
tion rate (eGFR) was also calculated [7].
Data analysis
Patients were stratified into three groups according to the
level of FEV1 loss to determine whether even a slight
FEV1 loss (0–20% predicted value) was associated with an
increased risk of lung cancer; i.e., < 0% predicted (stratum
1), 0–20% predicted (stratum 2) and > 20% predicted
(stratum 3). A univariate logistic regression analysis was
used to evaluate the association, which was presented as
an odds ratio (OR) and 95% confidence interval (CI), be-
tween FEV1 loss stratum membership and the presence of
lung cancer. This association was tested in unadjusted and
adjusted models that controlled for smoking exposure in
pack years. Patients exhibiting an FEV1 loss of < 0% pre-
dicted formed the reference group.
A risk prognosis model based on multiple logistic re-
gression analysis was used to evaluate the association be-
tween active smoking exposure and FEV1 loss with the
risk of lung cancer. The difference in risk (Δ) at an FEV1
loss of 56% (95th percentile) and −22% of the predicted
values (5th percentile) was normalized to the maximum
possible increase in risk for a given smoking exposure as
follows: Δnorm =Δ/(1 – risk at an FEV1 loss of −22% of
the predicted value). In a second step, the association of
smoking exposure and FEV1 loss with the predicted risk
of lung cancer was adjusted for age and sex.
The CRP levels displayed a skewed distribution and
were transformed to their natural logarithms (ln) to
achieve normality. A linear regression model was used to
analyze the effect of lung cancer on ln (CRP) before ad-
justment and after the first adjustment for the following
prospectively defined confounders: body mass index
(BMI) [8], age [9], and eGFR [10] as continuous variables,
and the smoking status at the time of referral (current ver-
sus never or ex-smoker) [11], sex [12], and the presence of
active malignant disease or heart disease [13] (see Table 1
for definition) as categorical variables. In the second step,
the values for ln (CRP) were additionally adjusted for
FEV1 loss. The change in the standardized regression co-
efficient (β) was used to determine the extent to which the
second adjustment attenuated the effect of lung cancer on
ln (CRP) compared to the first adjustment. A sensitivity
analysis was conducted to assess the effect of choosing a
value of 0.35 mg/L for patients with undetectable CRP
levels. This analysis compared the results obtained with
0.35 mg/L with those obtained with CRP values of 0.01
mg/L and 0.70 mg/L, respectively.
The effect of smoking exposure on FEV1 loss was sep-
arately analyzed for patients with lung cancer and pa-
tients with other cancers using linear regression.
Given the exploratory nature of this study, the test re-
sults should not be interpreted as confirmatory, and no
adjustments for multiple tests were performed. A p-
value < 0.05 was considered significant. The analyses
were performed using SAS version 9.4 (SAS Institute,
Chicago, IL, USA).
Results
Table 1 shows the demographic and clinical characteris-
tics of the entire study group and their distribution ac-
cording to the three strata of FEV1 loss. We observed
408 malignancies in the 368 patients with other cancers.
Of the 40 patients with multiple tumors, 30 had different
tumors. The most frequent entities were the following:
breast cancer (n = 105), prostate cancer (n = 56), colorec-
tal cancer (n = 37), and lymphomas (n = 70). Active ma-
lignant disease was present in 68% of the 107 patients
with lung cancer and in 28% of patients with other can-
cers (p < 0.01).
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The median [interquartile range] time intervals be-
tween cancer diagnosis and referral were 0.8 [0.3, 17.7]
months for patients with lung cancer and 58.9 [19.5,
121.7] months for patients with other cancers (p < 0.01).
The time interval between the cancer diagnosis and re-
ferral was > 5 years in 10% of patients with lung cancer
and in 49% of patients with other cancers. Of the 29 pa-
tients with lung cancer who were diagnosed > 1 year be-
fore referral, none continued to smoke after receiving
this diagnosis. The median time interval between the
lung cancer diagnosis and referral was 42.0 [24.5, 116.5]
months in this subgroup. Fourteen of the 29 patients ex-
hibited an FEV1 ranging from < 80–50% of the predicted
value, and 3 patients exhibited an FEV1 < 50% of the
predicted value. The median time interval between the
first cancer diagnosis and referral was 73.8 [39.1, 147.5]
months in patients with other cancers who were diag-
nosed > 1 year prior to referral. Sixteen of these 308 pa-
tients were current smokers at the time of referral.
A restrictive ventilatory defect was present in 66 pa-
tients, 37 of whom had evidence of pulmonary restriction
(parenchymal lung disease, 16 patients; prior lung resec-
tion surgery, 21 patients), and 19 had extra-pulmonary re-
striction due to the presence of pleural effusion (n = 8),
pleural fibrosis (n = 5) or diaphragm paralysis (n = 6). Ten
patients had no evidence of an underlying benign pleuro-
pulmonary disease or diaphragm weakness.
The patients exhibiting an FEV1 loss from 0 to 20% of
the predicted value had a higher odds of lung cancer
than patients assigned to the reference group before (OR
3.07, 95% CI 1.52–6.22) and after adjustment (OR 2.61,
95% CI 1.26–5.45) for smoking exposure. Both smoking
exposure and FEV1 loss were associated with the pre-
dicted risk of lung cancer (p < 0.01), as illustrated in
Fig. 2. The risk of lung cancer was 0.07 at 0 pack years if
the FEV1 loss was at the 5th percentile (−22% of the pre-
dicted value). Moving up the trajectory from the 5th to
the 95th percentile for FEV1 loss (56% of the predicted
value) while the smoking exposure was maintained at 0
pack years, increased the lung cancer risk to 0.23 (Δ =
0.16; Δnorm = 0.18). At the 95
th percentile of smoking ex-
posure (70 pack years), an increase from the 5th to the
95th percentile for FEV1 loss increased the risk of lung
cancer from 0.39 to 0.73 (Δ = 0.34; Δnorm = 0.55). The
values for Δ increased from 0.16 at 0 pack years, to 0.24
at 20 pack years, to 0.31 at 40 pack years, and the values
reached their maximum (0.34) at 61 pack years, followed
by a decrease with a further increase in smoking expos-
ure without reaching the zero mark, as illustrated in
Fig. 3. This figure also shows that the graph Δnormversus
Table 1 Demographic and clinical characteristics in the entire study group and in the three strata of FEV1 loss
aMean value ± 1 standard deviation
bChi square test
cOne way analysis of variance
dKruskal-Wallis test
eHistory of coronary artery disease defined as either angiographically proven coronary artery disease or a hospital diagnosis of myocardial infarction, presence of
atrial fibrillation, impaired left ventricular systolic function (ejection fraction <50%), significant valvular heart disease, pulmonary hypertension, or left ventricular
hypertrophy. Comprehensive definitions of these conditions are in given in reference 3
fResidual tumor at the time of referral or time interval between cancer surgery/end of chemotherapy/radiotherapy and referral <3 months
gEstimated glomerular filtration rate
hFEV1 loss [% predicted] = 100% - FEV1 % predicted
iNumbers of patients with {squamous cell cancer – adenocarcinoma – other histologic subtype}
jMedian value, with interquartile range in brackets
kFisher’s exact test, distribution of histologic subtypes
lOne way analysis of variance for the log transformed values
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number of pack years exhibited an almost linear increase
from 0 to approximately 70 pack years and flattened out
beyond this level of smoking exposure without reaching
a plateau. The effects of smoking exposure and FEV1
loss on the predicted risk of lung cancer remained sig-
nificant (p < 0.01) after adjustment for age (p = 0.48) and
sex (p = 0.06).
Among the 107 patients with lung cancer (83 men and
24 women), 14 (1 man and 13 women) and 93 (82 men
and 11 women) were never smokers and ever smokers,
respectively. Squamous cell carcinoma was diagnosed in
40 patients (37%), followed by adenocarcinoma (n = 38;
36%) and other subtypes (n = 29; 27%). Ever smokers
with an FEV1 loss > 20% of the predicted value had
higher odds of lung cancer than smokers with an FEV1
loss that did not exceed 20% (OR 2.69, 95% CI 1.60–
4.63). This odds ratio remained significant after adjust-
ing for smoking exposure (OR 2.13, 95% CI 1.21–3.75).
When restricting the analysis to the 203 patients who
had a ≥ 10 pack-year history of smoking (36 [20–50]
pack years), the patients with an FEV1 loss > 20% of the
predicted value (n = 104; 40 [30–60] pack years) had a
higher odds of lung cancer (OR 2.04, 95%-CI 1.16–3.58)
than patients with an FEV1 loss ≤ 20% of the predicted
value (n = 99; 30 [15–50] pack years).
The 177 patients with active malignant disease had
higher (p < 0.01, t-test for log transformed values) CRP
levels (8.40 [3.50–26.20] mg/L) than patients with in-
active disease (2.50 [1.30–6.60] mg/L). The mean log
transformed values for ln (CRP) were higher in the pa-
tients with lung cancer than in the patients with other
cancers in the unadjusted analysis (2.40 vs 1.24). Pa-
tients with lung cancer were approximately four times
more likely to have a CRP level above the median (4.05
mg/L) than patients with other cancers (OR 4.49, 95%
CI 2.74–7.35). The effect of lung cancer on ln (CRP)
remained significant (2.18 vs 1.49) after adjusting for
BMI (p = 0.05), age (n.s.), eGFR (n.s.), smoking status at
the time of referral (p = 0.02), sex (n.s.), the presence of
active malignant disease (p < 0.01), and the presence of
heart disease (p = 0.03). After the additional adjustment
for FEV1 loss (p < 0.01), ln (CRP) and smoking status at
the time of referral were no longer associated (p = 0.63),
Fig. 2 Impact of smoking exposure (pack years, x axis) and FEV1 loss (% of the predicted value, y axis) on the patient’s predicted risk of lung cancer (z
axis, vertical axis) as determined by a risk prognosis model based on multiple logistic regression analysis. This model allows to estimate the patient’s
risk of lung cancer (z) from the number of pack years (x) and FEV1 loss (y) using the following formula: z ¼ 1
1þe− −2:2296þ0:0312xþ0:0183yð Þð Þ. The data from all
patients were included in the regression analysis. The x and y axes of the figure were limited to 0 to 70 pack years (95th percentile) and −22% to 56%
of the predicted value (5th−95th percentile), respectively, to minimize disproportionate effects of extreme values on the graph. The graph has a color
code starting with green for a low predicted risk and ending with bluish-purple for a high predicted risk for lung cancer. A visualization tool that allows
a three-dimensional display of the relationship between smoking exposure, FEV1 loss and the risk of lung cancer from various angles is available on
the internet via http://www.ortenau-klinikum.de/fileadmin/resources/downloads/dr-wieshammer/smoking-exposure-3d-graph.exe
Fig. 3 Differences between the risks of lung cancer (Δ; solid lines) at an
FEV1 loss of 56% of the predicted value (95th percentile) and −22% of
the predicted value (5th percentile) for smoking exposures from 0 to 70
pack years (95th percentile; left panel) and over the whole range (0–200
pack years; right panel). The difference between the two risks (Δ) was
normalized (normalized difference in risk; Δnorm; dotted lines) to the
maximum possible increase in risk for a given smoking exposure using
the formula: Δnorm ¼ Δ1– risk at a FEV1 loss of −22 % of the predicted valueð Þ½ 
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whereas the effects of BMI (p = 0.02), the presence of
active malignant disease (p < 0.01), and the presence of
heart disease (p = 0.04) on ln (CRP) persisted. The sec-
ond adjustment for FEV1 loss attenuated the effect of
lung cancer on ln (CRP) by 15.2%, as indicated by the
change in β for lung cancer (0.197 vs 0.167). In the fully
adjusted model, the values for ln (CRP) were still higher
in the patients with lung cancer than in patients with
other cancers (2.09 vs 1.51). The former group still had
a nearly three-fold higher risk of having a CRP level
above the median (OR 2.67, 95% CI 1.50–4.75).” Lung
cancer” was compared to the other covariates to illus-
trate the magnitude of the effect of this predictor vari-
able on ln (CRP). In the fully adjusted model, “lung
cancer” had a 2.19-fold greater effect on ln (CRP) than
“heart disease” and the same effect as an increase in
FEV1 loss of 47% of the predicted value. Choosing a
CRP value of 0.35 mg/L for patients with undetectable
CRP values had a negligible effect on the results of the
regression analyses and no effect on the CRP values
presented in the table.
The effect of smoking exposure on FEV1 loss differed
in patients with lung cancer compared to patients with
other cancers. Figure 4 shows that the slope of this re-
lationship was higher in patients with other cancers
(4.6% predicted per 10 pack years vs 2.7% predicted per
10 pack years, p = 0.03), whereas the baseline level at 0
pack years was higher in patients with lung cancer
(15.2% vs 1.3% predicted, p < 0.01). The 95% CIs of the
two curves began to overlap at approximately 30 pack
years. The estimated crossover point was at 74 pack
years, corresponding to an FEV1 loss of 36% of the
predicted value.
Discussion
The principal findings of this study are that FEV1 loss is a
predictor of lung cancer risk after controlling for smoking
exposure and that this effect of FEV1 loss increases with
increasing smoking exposure. A FEV1 loss of 20% of the
predicted value is often considered the upper limit of the
normal range. An increase in FEV1 loss from a median
value of −10% (stratum 1) to even as little as 9% of the
predicted value (stratum 2) was associated with increased
risk of lung cancer after adjusting for smoking exposure.
Among the 153 patients assigned to stratum 1, 18.3% were
ever smokers, and 7.2% had lung cancer. Stratum 1 mem-
bership does not imply that no smoking-related FEV1 loss
had occurred because the pre-exposure values of FEV1
loss were not available. Our data only allowed for a single
comparison of an individual’s FEV1 loss with the external
predicted values. Even an FEV1 loss < 0% of the predicted
value may be significantly higher than this individual’s true
normal value.
The predicted values for lung cancer risk lie within the
range of [0–1]. A patient with a risk close to 1 due to a
high smoking exposure is less able to increase his or her
FEV1 loss-related risk when moving from the 5th (−22%
of the predicted value) to the 95th percentile (56% of the
predicted value) of this variable than a never smoker.
This limitation of Δ gives Δnorm an advantage as an out-
come variable. In a patient with a smoking exposure of
70 pack years who moved from the 5th to the 95th per-
centile of FEV1 loss, the lung cancer risk increased by
0.34, which was approximately two-fold higher than the
increase observed in never smokers (Δ = 0.16). The
values for Δnorm showed an almost linear increase up to
approximately 70 pack years and then levelled off with-
out reaching a plateau up to an exposure of 200 pack
years. Our data are inadequate to obtain a firm conclu-
sion on this point because only 21 patients reported a
smoking exposure above 70 pack years, 11 of whom had
lung cancer. Furthermore, the effect of smoking expos-
ure on lung cancer risk becomes so dominant at ≥ 70
pack years that the impact of FEV1 loss as an additional
predictive variable is difficult to recognize.
Current guidelines recommend criteria for selecting indi-
viduals without symptoms and signs of lung cancer for
screening using low-dose helical computed tomography.
These criteria include patients (i) 50 years of age or older
(ii) with a ≥ 20 pack-year history of smoking and (iii) the
presence of at least one additional risk factor, such as radon
exposure, occupational exposure, a cancer history, a family
history of lung cancer in first-degree relatives, pulmonary
fibrosis, or COPD [14]. In this study, an FEV1 loss > 20% of
the predicted value was associated with increased odds of
lung cancer among smokers with a ≥ 10 pack-year history.
Thus, in addition to calculating the number of pack years,
measurements of FEV1 loss are useful as a diagnostic tool
Fig. 4 Relationship between smoking exposure and FEV1 loss (%
of the predicted value) with 95% CIs as shaded bands around
the trend lines in patients with lung cancer (solid lines) and
other cancers (dotted lines) from the 5th (0 pack years) to the
95th percentile (70 pack years) of the predictor variable
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to identify smokers who are facing a particularly high risk
of developing lung cancer.
Our data cannot determine whether FEV1 loss is a direct
driving factor in lung carcinogenesis. We presume that
FEV1 loss is more of a surrogate marker of the carcinogenic
damage and the extent of disease progression rather than a
direct participant in the underlying disease process.
The prevalence values for lung cancer and COPD were
40 and 44% among ever smokers, respectively. Epidemio-
logical studies of the general population have shown that
the majority of ever smokers do not develop lung cancer
or COPD. The lifetime risk of lung cancer is only 15%
among ever smokers. Approximately 50–80% of patients
with lung cancer have COPD. Although the traditional
view has been that the prevalence of COPD among ever
smokers is only 20–30% [15], one study suggested that as
many as one in two smokers may eventually develop
COPD, provided that they live long enough [16]. The in-
clusion criteria of our study are crucial for interpreting
the results. The presence of both a previous or active can-
cer and cardiac or pulmonary symptoms were prerequi-
sites for inclusion. The cohort did not include any healthy
smokers. A smoker who was less susceptible to developing
COPD was more likely to be asymptomatic and thus less
likely to be included in this study than a COPD-
susceptible smoker. Hence, our findings overestimate the
strength of the relationship between smoking exposure
and FEV1 loss, particularly in patients with other cancers.
This referral bias does not invalidate the main finding of
our study. Rather, the study design provides insights into
the relationship between smoking exposure and FEV1 loss
in determining lung cancer risk as if it were viewed under
a magnifying glass.
We included patients with asthma without evidence of
airway obstruction and did not exclude patients with re-
strictive ventilatory defects. As shown in Table 1, the FEV1
loss strata 1 and 2 were well balanced with respect to pa-
tients with asthma, whereas patients with restrictive ventila-
tory defects were not evenly distributed across the three
strata of FEV1 loss. There is no epidemiologic evidence of
an association between asthma and lung cancer [17], and
none of our information suggests that the inclusion of pa-
tients with asthma introduced any bias. In patients with re-
strictive ventilatory defects, the FEV1 % predicted values
were adjusted for the VC % predicted values instead of the
TLC % predicted values if the VC % predicted value was
greater than TLC % predicted value [18]. This adjustment
was made (i) because the VC % predicted value is less sub-
ject to measurement error than the TLC % predicted value
and (ii) to maintain a minimum difference between the
measured and adjusted FEV1 % predicted values.
The time interval between cancer diagnosis and lung
function testing was > 1 year in 27% of patients with
lung cancer and in 84% of patients with other cancers.
Thus, the values for FEV1 loss differed significantly at
the two time points in a number of these patients. The
rate of decrease in FEV1 varies, with increasing rates ob-
served among current smokers and patients with bron-
chodilator reversibility or emphysema [19]. Therefore,
we refrained from estimating the FEV1 loss at the time
of cancer diagnosis by extrapolating backwards in time
from the FEV1 loss observed at the time of referral and
used the latter value for the statistical analyses.
Direct markers of airway inflammation were not avail-
able. The serum CRP level has gained acceptance as an
indirect and quantitative marker of airway inflammation.
In patients with stable COPD, the serum CRP levels are
positively correlated both with FEV1 loss and an acceler-
ated rate of decrease in FEV1 over time [20–23]. If ln
(CRP) were only a surrogate marker of FEV1 loss, the
second adjustment of ln (CRP) would be expected to
equalize the difference in ln (CRP) between patients with
lung cancer and patients with other cancers, but this hy-
pothesis was not confirmed. The values for ln (CRP)
remained significantly higher in patients with lung can-
cer after adjusting for FEV1 loss. These findings are con-
sistent with the hypothesis that airway inflammation
exerts a unique role in determining the patient’s risk of
developing lung cancer. Because our data are cross-
sectional, no causal relationships can be established. Ra-
ther, the results of this study are purely descriptive and
provide no insights into the time course and interactions
by which smoking exposure, FEV1 loss and inflamma-
tion influence the development of lung cancer.
This single-center study has further limitations. First,
the data on smoking exposure were collected retrospect-
ively. Many patients with symptomatic COPD or lung
cancer feel guilty about smoking. Patients with lung can-
cer or symptomatic COPD who report no or a low
smoking exposure might thus have systematically under-
reported their smoking exposure compared to patients
without smoking-related lung disease. If this kind of
reporting bias had occurred, the true associations of
smoking exposure with lung cancer risk and FEV1 loss
were stronger than the values we estimated. We cannot
discount this possibility; however, we found no support
in the literature for this assumption. Second, the smok-
ing status at the time of referral was not objectively vali-
dated. Third, other risk factors for lung cancer – e.g., a
family history of lung cancer, the presence of pulmonary
fibrosis and exposure to second-hand smoke, radon, gas,
asbestos and other substances known to cause lung can-
cer – were not included in our risk prognosis model due
to a paucity of and a lack of data. Fourth, the number of
patients with lung cancer was too low to determine sex-
and age-specific risks and to differentiate between histo-
logical types of lung cancer [24–26]. Fifth, the scope of
this study was limited to FEV1 loss and did not address
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the role of emphysema in determining the patient’s pre-
dicted risk of lung cancer. Sixth, we did not exclude pa-
tients with coexisting acute infections or chronic non-
malignant inflammatory disorders nor did we adjust the
ln (CRP) values for these conditions. Hence, the back-
ground noise that influenced the CRP level was high.
This limitation tends to dilute the effect of inflammation
in the lung on the CRP level and therefore does not
weaken the strength of our findings. Finally, the 368 pa-
tients with other cancers constitute a heterogeneous co-
hort that is specific to this institution. Our findings are
not generalizable to other populations.
Conclusion
FEV1 loss is a predictor of lung cancer risk. The ef-
fect of FEV1 loss on this outcome increases with the
level of previous smoking exposure. In addition to
calculating the number of pack years, measurements
of FEV1 loss are a useful method to identify patients
facing an increased risk of developing lung cancer.
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